A multicenter gastroenterology consortium establishes a prospective registry to evaluate the risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. On January 1, 2020, the team screens 258 patients and excludes 4 who already have evidence of malignancy. The remaining 254 disease-free patients are followed until December 31, 2024.
During this exact 5-year observation period, the following events are recorded among the enrolled cohort:
- 30 patients are diagnosed with cholangiocarcinoma exactly 24 months after enrollment.
- 50 patients are lost to follow-up exactly 36 months after enrollment, with no evidence of malignancy prior to that point.
- 20 patients die from unrelated causes exactly 12 months after enrollment, without developing the cancer.
- The remaining patients complete the full 5-year follow-up period without developing the disease.
Assuming no other patients enter or leave the study, what is the incidence rate of cholangiocarcinoma in this cohort, expressed as cases per person-years?
Answer: 30 cases